It is with a mix of sadness and gratitude that Cancer Therapeutics CRC (CTX) announces the resignation of Dr George Morstyn from the Board of Directors. George was appointed to the Board in 2008 and since then the organisation has benefited from the wealth of knowledge he has acquired during his outstanding career in medical research and the biotech industry.
George has had a distinguished career and was head of the clinical program at the Ludwig Institute for Cancer Research in Melbourne and Principal Investigator on the earliest clinical studies of haemopoietic growth factors, the CSFs. From 1991 to 2002, he worked for Amgen, rising to Senior Vice President of Development and Chief Medical Officer in 1999. Dr Morstyn continues as Chair of the scientific advisory board of Symbio (Japan) and as a board member of Actinogen and Limos.
Commenting, Dr Tony Evans Chair of CTX, said: “I would like to thank George for his dedication to our organisation over the past 10 years. George has made many deep and thoughtful contributions to CTX and we will miss that insight. With a long and distinguished career in medical research and biotechnology driven drug development CTX is fortunate indeed to count George among its family.”
The Board and Senior Management team at CTX thank George for his many years of service and wish him every happiness in the future.